What types of tumors are Sorafenib/Nexavar mainly used to treat?

Sorafenib/Nexavar (Sorafenib) is an oral small molecule multi-target tyrosine kinase inhibitor that has played an important role in the field of tumor treatment since its introduction. It mainly targets key signaling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and RAF kinase, so it has significant advantages in inhibiting tumor cell proliferation and angiogenesis. Sorafenib was first approved for the treatment of advanced hepatocellular carcinoma (HCC), especially for patients with unresectable or recurrent disease, providing an oral targeted therapy option for long-term disease management.

In addition to liver cancer, sorafenib is also widely used in the treatment of clear cell renal cell carcinoma (RCC) and some types of thyroid cancer. In patients with advanced kidney cancer, sorafenib can delay disease progression and improve patient survival by inhibiting angiogenesis and cell proliferation signals. For advanced or refractory thyroid cancer, especially differentiated or dedifferentiated thyroid cancer, sorafenib has also demonstrated the ability to inhibit tumor growth and has become an important choice in multi-line treatment options.

In clinical practice, the application of sorafenib not only depends on the tumor type, but also needs to be combined with the patient's overall condition and tumor molecular characteristics. For patients with liver cancer, previous liver function, portal vein thrombosis and degree of liver cirrhosis will affect the safety of medication; for patients with kidney cancer and thyroid cancer, previous treatment experience and tumor stage also need to be considered. This concept of personalized medicine reflects the status of sorafenib in modern precision cancer treatment.

In general, sorafenib is mainly used for the treatment of advanced hepatocellular carcinoma, advanced renal cell carcinoma and some thyroid cancers. It is also exploring other solid tumor indications in clinical trials. Through multi-target inhibition, it provides late-stage patients with long-term treatment options to control tumors and delay progression. With the accumulation of more clinical experience and the publication of research results, the scope of application and treatment strategies of sorafenib are expected to be further expanded and bring more benefits to patients.

Reference materials:https://www.nexavar.com/